Desmopressin
Evidence: A — Established Human EvidenceRenal / Fluid-Balance Signaling
Evidence Snapshot
What this grade covers
A applies to Desmopressin's own directly-labeled, FDA-approved indications within their correct formulation: central diabetes insipidus (tablets, nasal spray, injection), primary nocturnal enuresis (TABLET FORMULATION ONLY), and hemostatic use in mild hemophilia A/Type I von Willebrand disease with Factor VIII >5% (Stimate and select injection product lines) — each has decades of clinical-trial-supported, FDA-labeled evidence. B applies to cross-formulation extrapolation of a labeled effect without confirming the specific product/route. C/D applies to any claim about the intranasal-enuresis use that the FDA specifically removed in 2007 for hyponatremia/seizure risk, or to a hemostatic percentage-response figure not traced to a single confirmable primary study in this review. E applies to any generalized 'Desmopressin is safe/approved for X' statement made without naming the specific formulation, and to the exact '61 cases/2 deaths' FDA figure specifically, which this review could not independently confirm against the FDA's own primary document text — that figure must be used only as attributed secondary reporting, never as an unqualified frozen number. This does not downgrade the overall A because the underlying route-specific regulatory action itself IS well-corroborated; only the exact case-count numeral is held back.
Regulatory Context
Desmopressin's FDA approval status is formulation-specific: separate approved indications exist for tablets (central diabetes insipidus, primary nocturnal enuresis), standard nasal spray (central diabetes insipidus only), injection (central diabetes insipidus, post-surgical/traumatic temporary polyuria, and in some products hemostatic use), and Stimate (hemostatic use in mild hemophilia A/von Willebrand disease Type I). No single 'Desmopressin is approved for X' statement applies across all formulations.
Research Takeaway
Desmopressin (DDAVP; 1-deamino-8-D-arginine vasopressin) is a synthetic AVP analogue with two specific modifications (N-terminal deamination; D-arginine at position 8) that extend its half-life and sharply increase its V2-receptor (antidiuretic/hemostatic) selectivity relative to V1a (pressor) activity.
See all 6 evidence claims →Quick Summary
Desmopressin (DDAVP) is a synthetic, V2-selective analogue of Arginine Vasopressin with decades of FDA-approved use across several distinct formulations — central diabetes insipidus, primary nocturnal enuresis (tablets only), and hemostatic support in mild bleeding disorders (Stimate/select injectables). Its major limitation is a well-established, formulation-specific hyponatremia/seizure risk that led the FDA to remove the enuresis indication from the intranasal formulation specifically, while leaving it in place for tablets.
Mechanism & Research Overview
Desmopressin (DDAVP) is a synthetic, V2-selective analogue of Arginine Vasopressin with decades of FDA-approved use across several distinct formulations — central diabetes insipidus, primary nocturnal enuresis (tablets only), and hemostatic support in mild bleeding disorders (Stimate/select injectables). Its major limitation is a well-established, formulation-specific hyponatremia/seizure risk that led the FDA to remove the enuresis indication from the intranasal formulation specifically, while leaving it in place for tablets.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Desmopressin (DDAVP; 1-deamino-8-D-arginine vasopressin) is a synthetic AVP analogue with two specific modifications (N-terminal deamination; D-arginine at position 8) that extend its half-life and sharply increase its V2-receptor (antidiuretic/hemostatic) selectivity relative to V1a (pressor) activity.
Sources: Structure-Activity Relationship of 1-Desamino-8-D-Arginine Vasopressin (Desmopressin)
Supported
Desmopressin's FDA-approved indications are formulation-specific: tablets cover central diabetes insipidus and primary nocturnal enuresis; nasal spray (DDAVP-concentration) covers central diabetes insipidus only; injection covers central diabetes insipidus and post-surgical/post-traumatic temporary polyuria; Stimate (higher-concentration nasal spray) and select injection products cover hemostatic use in mild hemophilia A/von Willebrand disease Type I.
Sources: FDA Label / DailyMed Record for DDAVP Tablets (Desmopressin Acetate); FDA Label / DailyMed Record for DDAVP Nasal Spray (Desmopressin Acetate), 2018; FDA Label / DailyMed Record for DDAVP Injection (Desmopressin Acetate); FDA Label / DailyMed Record for Stimate Nasal Spray (Desmopressin Acetate, 150 mcg/spray)
Supported
Intranasal desmopressin (DDAVP-concentration nasal spray) is no longer FDA-indicated for primary nocturnal enuresis; the tablet formulation retains this indication.
Does not establish
Evidence boundary: This is a route-specific restriction and must not be read as removing the enuresis indication from every Desmopressin formulation.
Sources: FDA December 2007 Postmarketing Safety Action on Intranasal Desmopressin (Enuresis Indication Removal); FDA Label / DailyMed Record for DDAVP Nasal Spray (Desmopressin Acetate), 2018
Supported
Desmopressin carries a hyponatremia/water-intoxication risk across all formulations, mechanistically linked to its V2-mediated antidiuretic action; the FDA specifically restricted intranasal pediatric-enuresis use following postmarketing reports of hyponatremia-related seizures, some of which were fatal.
Does not establish
Evidence boundary: Exact case counts are attributed to secondary reporting of the FDA's 2007 action and are not independently confirmed against the FDA's primary document text in this review.
Sources: FDA December 2007 Postmarketing Safety Action on Intranasal Desmopressin (Enuresis Indication Removal)
Supported
Desmopressin (Stimate/injection) raises endogenous Factor VIII and von Willebrand factor levels sufficiently to achieve hemostatic benefit in a majority of patients with mild hemophilia A or Type I von Willebrand disease with baseline Factor VIII activity above 5%.
Does not establish
Evidence boundary: Response rates vary by patient/product and this is not effective in severe hemophilia A or most von Willebrand disease subtypes.
Supported
All Desmopressin formulations require fluid-intake restriction around the dosing window and interruption during acute illnesses that risk fluid/electrolyte imbalance, per FDA labeling.
Sources: FDA Label / DailyMed Record for DDAVP Tablets (Desmopressin Acetate); FDA Label / DailyMed Record for DDAVP Injection (Desmopressin Acetate)
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Higher-Priority Safety Consideration
Mechanistically expected from V2-mediated antidiuresis; most severe historical signal is intranasal pediatric enuresis use, which triggered the 2007 FDA label restriction.Higher-Priority Safety Consideration
The population and use case (children treated for bedwetting) driving the 2007 restriction is itself part of the risk architecture, not incidental.Safety Consideration
Intranasal route carries materially higher hyponatremia/seizure risk than oral tablets at equivalent clinical use; must not be flattened into one 'Desmopressin risk' statement.Safety Consideration
The '61 cases/2 deaths' figure is well-corroborated by secondary sources but not independently confirmed against FDA primary text in this review; treat as attributed reporting, not a frozen primary-source number.
Research Areas Being Studied
Research areas discussed on this page reflect the Renal / Fluid-Balance Signaling category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| FDA Label / DailyMed Record for DDAVP Nasal Spray (Desmopressin Acetate), 2018 | 2018 | DDAVP Nasal Spray is indicated for central diabetes insipidus in adults and pediatric patients 4 years and older only; explicitly NOT indicated for primary nocturnal enuresis (removed per the 2007 FDA safety action). | No source link available | ||
| FDA December 2007 Postmarketing Safety Action on Intranasal Desmopressin (Enuresis Indication Removal) | 2007 | Intranasal desmopressin formulations lost the primary-nocturnal-enuresis indication specifically (tablets retained it) because of a disproportionate hyponatremia/seizure risk via the intranasal route. | The FDA's own primary safety-communication document text could not be directly fetched in this review (403/404 on direct fetch); the structural finding (which formulation lost which indication, and why) is corroborated by multiple independent secondary sources and is frozen, but the specific numeric figure reported by secondary sources ('61 hyponatremia-related-seizure cases, 2 deaths') is NOT independently confirmed against FDA primary text and must be used only as attributed secondary reporting, never as an unqualified frozen number. | No source link available | |
| FDA Label / DailyMed Record for DDAVP Injection (Desmopressin Acetate) | DDAVP Injection is indicated for central diabetes insipidus and for temporary polyuria/polydipsia following head trauma or pituitary surgery; some desmopressin acetate injection product lines also carry a labeled hemostatic indication in hemophilia A (Factor VIII >5%) and mild-to-moderate von Willebrand disease Type I. | No source link available | |||
| FDA Label / DailyMed Record for DDAVP Tablets (Desmopressin Acetate) | DDAVP Tablets are FDA-labeled for central diabetes insipidus and primary nocturnal enuresis; dosing titrated up to 0.6 mg, with fluid restriction directed from 1 hour before dosing through at least 8 hours after / the next morning. | No source link available | |||
| FDA Label / DailyMed Record for Stimate Nasal Spray (Desmopressin Acetate, 150 mcg/spray) | Stimate Nasal Spray (higher-concentration, 150 mcg/spray, distinct from DDAVP Nasal Spray) is labeled specifically for hemostatic use — raising Factor VIII and von Willebrand factor levels — in mild hemophilia A and Type I von Willebrand disease with Factor VIII activity above 5%. Not indicated for diabetes insipidus or enuresis. | No source link available |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| StatPearls: Desmopressin | General review/context reference on Desmopressin's pharmacology, formulations, and clinical use. | No source link available | |||
| Structure-Activity Relationship of 1-Desamino-8-D-Arginine Vasopressin (Desmopressin) | Reviews the two structural modifications distinguishing Desmopressin from native AVP (N-terminal deamination; D-arginine at position 8) and their effect on V2-receptor selectivity and duration of action. | No source link available |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes FDA-approved labeling and published research about Desmopressin across its various formulations and does not provide medical advice, individualized treatment recommendations, or dosing instructions.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated .
Follow research updates for Desmopressin
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.